Testing effectiveness (Phase 2)Ended earlyNCT04274023What this trial is testingStudy on TSR-042 in Advanced Clear Cell SarcomaWho this might be right forSarcoma, Clear Cell Italian Sarcoma Group 3
Not applicableLooking for participantsNCT07249060What this trial is testingInterferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease PatientsWho this might be right forImmune-Related Adverse EventsLupus Erythematosus, SystemicSjogren Syndrome+3 more Hospital Universitario Araba 300
Testing effectiveness (Phase 2)Study completedNCT04465890What this trial is testingA Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B PatientsWho this might be right forChronic Hepatitis b Ascletis Pharmaceuticals Co., Ltd. 207
Large-scale testing (Phase 3)Active Not RecruitingNCT05499390What this trial is testingAK112 in Advanced Non-Small Cell Lung CancerWho this might be right forAdvanced Non-small-cell Lung Cancer Akeso 398
Large-scale testing (Phase 3)Active Not RecruitingNCT04550260What this trial is testingStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCWho this might be right forEsophageal Squamous Cell Carcinoma AstraZeneca 640
Testing effectiveness (Phase 2)Ended earlyNCT03376659What this trial is testingDurvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic AdenocarcinomaWho this might be right forMetastatic Colorectal CancerColorectal AdenocarcinomaPancreatic Adenocarcinoma+1 more Georgetown University 8
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07762703What this trial is testingCombination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyWho this might be right forTriple-Negative Breast Cancer (TNBC) BreakBio Corp 10
Testing effectiveness (Phase 2)Looking for participantsNCT06580574What this trial is testingImmune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersWho this might be right forGastric CancerColon CancerMSI-H+1 more Peking University 34
Early research (Phase 1)Study completedNCT03517488What this trial is testingXmAb®20717 in Subjects With Selected Advanced Solid TumorsWho this might be right forMelanomaBreast CarcinomaHepatocellular Carcinoma+25 more Xencor, Inc. 150
Testing effectiveness (Phase 2)Looking for participantsNCT06941857What this trial is testingNC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerWho this might be right forPancreatic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Not applicableLooking for participantsNCT06227728What this trial is testingAnalysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.Who this might be right forNon Small Cell Lung CancerBreast CancerColorectal Cancer+4 more Gene Solutions 50
Large-scale testing (Phase 3)Study completedNCT03084471What this trial is testingAn Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.Who this might be right forAdvanced Solid Malignancies AstraZeneca 867
Large-scale testing (Phase 3)Study completedNCT04676412What this trial is testingEfficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension StudyWho this might be right forNon-small Cell Lung Cancer Merck Sharp & Dohme LLC 107
Testing effectiveness (Phase 2)Looking for participantsNCT07106892What this trial is testingPhase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal CancerWho this might be right forColorectal Cancer (CRC) Shanghai Henlius Biotech 60
Testing effectiveness (Phase 2)WithdrawnNCT03197571What this trial is testingQUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWho this might be right forUrothelial Carcinoma ImmunityBio, Inc.
Early research (Phase 1)Ended earlyNCT04156100What this trial is testingA Study in Subjects With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor Agenus Inc. 19
Very early researchUnknownNCT03371992What this trial is testingPilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLCWho this might be right forNon Small Cell Lung Cancer Nilogen Oncosystems 25
Testing effectiveness (Phase 2)Ended earlyNCT03440437What this trial is testingFS118 in Patients With Advanced MalignanciesWho this might be right forAdvanced CancerMetastatic CancerSquamous Cell Carcinoma of Head and Neck invoX Pharma Limited 80
Large-scale testing (Phase 3)Active Not RecruitingNCT04634877What this trial is testingStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Who this might be right forEndometrial Neoplasms Merck Sharp & Dohme LLC 990
Testing effectiveness (Phase 2)Ended earlyNCT03666728What this trial is testingSHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLCWho this might be right forLung Neoplasms Jiangsu HengRui Medicine Co., Ltd. 5